Team:Wageningen UR
From 2012.igem.org
TSlijkhuis (Talk | contribs) |
|||
Line 47: | Line 47: | ||
<h2 class="ulc2">Medal Achievements</h2> | <h2 class="ulc2">Medal Achievements</h2> | ||
- | < | + | <div class="achievement"> |
- | + | ||
+ | We submitted a new and well characterised standard BioBrick: CCMV wt [link to BioBrick Code] | ||
+ | |||
+ | <div class="achievement-desc"> | ||
This BrioBrick can be used to produce wild type CCMV Virus-Like particles. Besides, it can serve as a template for modifications to pursue many new applications (link to apps). The sequence is confirmed. | This BrioBrick can be used to produce wild type CCMV Virus-Like particles. Besides, it can serve as a template for modifications to pursue many new applications (link to apps). The sequence is confirmed. | ||
+ | </div> | ||
+ | |||
+ | </div> | ||
* We demonstrated that the production of VLPs using our own BioBricks works. | * We demonstrated that the production of VLPs using our own BioBricks works. | ||
Line 71: | Line 76: | ||
By cooperating with most of the Dutch iGEM teams, we managed to have a nation-wide appearance in three major cities during the Discovery Festivals [link website R’dam]. Our team presents the science of iGEM in Rotterdam, while being analysed by a student in Applied Communication [link Paulien]. | By cooperating with most of the Dutch iGEM teams, we managed to have a nation-wide appearance in three major cities during the Discovery Festivals [link website R’dam]. Our team presents the science of iGEM in Rotterdam, while being analysed by a student in Applied Communication [link Paulien]. | ||
- | |||
- | |||
Revision as of 15:41, 19 September 2012
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
The Constructor
An application that assists you in creating your cloning strategies for your iGEM project.